Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-DOTA-daratumumab
- Development stage
- Phase 1
- Lead developer
- City of Hope National Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
64Cu-DOTA-daratumumab is a radiopharmaceutical imaging agent developed by City of Hope Medical Center for the detection and monitoring of multiple myeloma. It consists of the human monoclonal antibody daratumumab, which targets the CD38 protein highly expressed on plasma cells, conjugated to the DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelator and labeled with the positron-emitting radioisotope copper-64 (64Cu). This tracer is designed for use with positron emission tomography (PET) imaging to evaluate disease extent, monitor treatment response, and potentially offer higher sensitivity than standard 18F-FDG PET/CT in patients with newly diagnosed or relapsed multiple myeloma.
- Other names
- copper 64Cu-DOTA-daratumumabcopper64Cu-DOTA-daratumumabcopper-64Cu-DOTA-daratumumab64Cu-labeled daratumumab64Cu-DOTA-Daratumumab PET
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on 64Cu-DOTA-daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-DOTA-daratumumab.